<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893984</url>
  </required_header>
  <id_info>
    <org_study_id>pre001</org_study_id>
    <nct_id>NCT00893984</nct_id>
  </id_info>
  <brief_title>Alternative in Beta Blocker Intolerance: The ABBI Trial</brief_title>
  <acronym>ABBI</acronym>
  <official_title>Alternative in Beta Blocker Intolerance; the ABBI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in
      cardiovascular patients who are not able to tolerate conventional beta blockers. A side
      effect profile will be tracked and compared with previous beta blocker use.

      The investigators hypothesize that Bystolic will be tolerated by many patients who are
      intolerant of conventional blockers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have been prescribed standard beta blockers but were unable to tolerate them due
      to side effects will be studied. They will take a new beta blocker, Nebivolol (Bystolic) for
      30 days, if tolerated. Side effects will be tracked and compared to previous.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient recruitment
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of intolerance of Bystolic, measured by side effect(s) that lead to discontinuance of Bystolic by the patient and/or the physician</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reason for termination of Bystolic</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of same symptom stopping Bystolic as previous beta blocker</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 21

          -  Male or female who is post-menopausal or not pregnant and using an approved
             contraceptive regimen

          -  Previous beta blocker use and intolerant of beta blocker

        Exclusion Criteria:

          -  Systolic blood pressure &lt; 100 mmHg unless another blood pressure medication is stopped
             at the time of study entry

          -  Hospitalized for heart failure within the past 4 weeks

          -  Bradycardia with a heart rate &lt; 60

          -  Heart block greater than first degree

          -  History of sick sinus syndrome (unless a permanent pacemaker is in place)

          -  History of severe hepatic or renal dysfunction; serum Creatinine &gt; 2.0 or Amylase &gt; 3x
             normal

          -  Use of CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)

          -  Ingestion of investigational drug within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minneapolis Heart Institute at Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mplsheart.com/</url>
    <description>Minneapolis Heart Institute</description>
  </link>
  <link>
    <url>http://www.mplsheart.org/</url>
    <description>Minneapolis Heart Institute Foundation</description>
  </link>
  <reference>
    <citation>Wojciechowski D, Papademetriou V. Beta-blockers in the management of hypertension: focus on nebivolol. Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. doi: 10.1586/14779072.6.4.471. Review.</citation>
    <PMID>18402537</PMID>
  </reference>
  <reference>
    <citation>Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens. 2005 Dec;18(12 Pt 2):169S-176S. Review.</citation>
    <PMID>16373195</PMID>
  </reference>
  <reference>
    <citation>Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, Hoffman BS, Allen LaPointe N, Peterson E. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006 Sep;152(3):454.e1-8.</citation>
    <PMID>16923412</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intolerance</keyword>
  <keyword>Beta blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

